ATE325610T1 - Xanthinderivative zur behandlung von hirnischämie - Google Patents

Xanthinderivative zur behandlung von hirnischämie

Info

Publication number
ATE325610T1
ATE325610T1 AT98941725T AT98941725T ATE325610T1 AT E325610 T1 ATE325610 T1 AT E325610T1 AT 98941725 T AT98941725 T AT 98941725T AT 98941725 T AT98941725 T AT 98941725T AT E325610 T1 ATE325610 T1 AT E325610T1
Authority
AT
Austria
Prior art keywords
schemia
brain
treatment
xanthine derivatives
xanthine
Prior art date
Application number
AT98941725T
Other languages
English (en)
Inventor
Junichi Shimada
Masako Kurokawa
Ken Ikeda
Fumio Susuki
Yoshihisa Kuwana
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Application granted granted Critical
Publication of ATE325610T1 publication Critical patent/ATE325610T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
AT98941725T 1997-09-05 1998-09-04 Xanthinderivative zur behandlung von hirnischämie ATE325610T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP24056597 1997-09-05

Publications (1)

Publication Number Publication Date
ATE325610T1 true ATE325610T1 (de) 2006-06-15

Family

ID=17061422

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98941725T ATE325610T1 (de) 1997-09-05 1998-09-04 Xanthinderivative zur behandlung von hirnischämie

Country Status (8)

Country Link
US (4) US6727259B2 (de)
EP (2) EP1666041A3 (de)
JP (1) JP2009102334A (de)
AT (1) ATE325610T1 (de)
AU (1) AU734138B2 (de)
DE (1) DE69834500T2 (de)
ES (1) ES2264210T3 (de)
WO (1) WO1999012546A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0306919A (pt) 2002-01-28 2004-11-09 Kyowa Hakko Kogyo Kk Métodos para reduzir ou suprimir a efetividade adversa da terapia de l-dopa e/ou do agonista da dopamina, e para tratamento moderado de l-dopa, composição para tratamento moderado de l-dopa, método para tratar doença de parkinson e/ou complicações motoras de l-dopa, composição para o tratamento da doença de parkinson, e, métodos para prolongar o tratamento eficaz da doença de parkinson, e para tratar os distúrbios de movimento
AR039385A1 (es) * 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
AR056615A1 (es) * 2002-12-27 2007-10-17 Kyowa Hakko Kogyo Kk Un metodo de tratamiento de trastornos de la conducta
US8202869B2 (en) 2003-06-10 2012-06-19 Kyowa Hakko Kirin Co., Ltd. Method of treating an anxiety disorder
TW200507850A (en) * 2003-07-25 2005-03-01 Kyowa Hakko Kogyo Kk Pharmaceutical composition
JPWO2005053695A1 (ja) * 2003-12-04 2007-12-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 多発性硬化症予防剤または治療剤
US20070078148A1 (en) * 2003-12-09 2007-04-05 Kyowa Hakko Kogyo Co., Ltd. Agents for preventing and/or treating higher brain dysfunctions
EP1709967A4 (de) 2004-01-28 2010-09-15 Kyowa Hakko Kirin Co Ltd Mittel zur behandlung von migräne
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
UY30267A1 (es) * 2006-04-13 2007-11-30 Astrazeneca Ab Nuevos derivados de la tioxantina , composiciones farmacéuticas que los contienen, procedimientos de preparacion y aplicaciones
TW200804383A (en) 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938
JP5765239B2 (ja) * 2009-03-13 2015-08-19 アドヴィナス・セラピューティックス・リミテッド 置換縮合ピリミジン化合物
UA110097C2 (uk) 2009-09-02 2015-11-25 Терапевтичний агент для лікування розладів настрою
UA113383C2 (xx) 2009-09-02 2017-01-25 Терапевтичний агент для лікування тривожних розладів
AU2013251079B2 (en) * 2012-04-20 2017-03-23 Ucb Pharma S.A. Methods for treating Parkinson's disease
JO3544B1 (ar) 2015-03-19 2020-07-05 Kyowa Kirin Co Ltd عامل علاجي للاختلال الوظيفي في الفص الجبهي

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3641010A (en) 1970-06-11 1972-02-08 Parke Davis & Co Novel xanthine compounds and means for obtaining the same
GB8610136D0 (en) * 1986-04-25 1986-05-29 Wellcome Found Compounds
US4772607A (en) * 1986-05-20 1988-09-20 Warner-Lambert Company Dialkenyl derivatives of xanthine, pharmaceutical compositions and methods of use therefor
DE8817122U1 (de) * 1988-12-22 1993-02-04 Boehringer Ingelheim Kg, 55218 Ingelheim Neue Xanthinderivate mit Adenosinantogenistischer Wirkung
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
FR2665636B1 (fr) * 1990-08-10 1994-10-07 Adir Utilisation d'un derive de la trimethyl-1,3,7 xanthine pour le traitement des troubles de la memoire, des troubles intellectuels de la senescence et de la maladie d'alzheimer.
EP0559893B1 (de) 1990-10-18 1999-02-03 Kyowa Hakko Kogyo Co., Ltd. Xanthinderivate
DE4307883A1 (en) * 1992-03-12 1993-09-23 Westarp Martin Egon Dr Med Use of anti-retroviral substances - to treat motor-neuronal diseases
US5484920A (en) 1992-04-08 1996-01-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for Parkinson's disease
CA2093403C (en) 1992-04-08 1999-08-10 Fumio Suzuki Therapeutic agent for parkinson's disease
JP2928386B2 (ja) * 1992-07-08 1999-08-03 協和醗酵工業株式会社 うつ病治療剤
JP2613355B2 (ja) * 1992-09-28 1997-05-28 協和醗酵工業株式会社 パーキンソン氏病治療剤
DE4236331A1 (de) 1992-10-28 1994-05-05 Boehringer Ingelheim Kg Synergistische Kombination
US5817662A (en) * 1992-11-09 1998-10-06 Cell Therapeutics, Inc. Substituted amino alkyl compounds
CA2112031A1 (en) 1992-12-24 1994-06-25 Fumio Suzuki Xanthine derivatives
JP3165769B2 (ja) * 1992-12-24 2001-05-14 協和醗酵工業株式会社 キサンチン誘導体
US5443836A (en) * 1993-03-15 1995-08-22 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage
WO1994025462A1 (en) * 1993-05-03 1994-11-10 The United States Of America, Represented By The 8-substituted 1,3,7-trialkyl-xanthine derivatives as a2-selective adenosine receptor antagonists
WO1995011681A1 (en) * 1993-10-29 1995-05-04 Merck & Co., Inc. Human adenosine receptor antagonists
AU1090795A (en) * 1993-11-12 1995-05-29 Cell Therapeutics, Inc. Method for preventing tissue injury from hypoxia
ES2312166T3 (es) 1994-02-23 2009-02-16 Kyowa Hakko Kogyo Co., Ltd Acelerador del crecimiento plaquetario.
ATE218139T1 (de) 1994-02-23 2002-06-15 Kyowa Hakko Kogyo Kk Xanthin-derivate
JPH0940652A (ja) * 1995-07-28 1997-02-10 Kyowa Hakko Kogyo Co Ltd ウラシル誘導体の製造方法

Also Published As

Publication number Publication date
US7115614B2 (en) 2006-10-03
US6727259B2 (en) 2004-04-27
EP1016407A4 (de) 2003-01-02
DE69834500D1 (de) 2006-06-14
EP1016407B1 (de) 2006-05-10
AU8997698A (en) 1999-03-29
WO1999012546A1 (en) 1999-03-18
ES2264210T3 (es) 2006-12-16
JP2009102334A (ja) 2009-05-14
US20040229888A1 (en) 2004-11-18
AU734138B2 (en) 2001-06-07
US20080207649A1 (en) 2008-08-28
US20030158214A1 (en) 2003-08-21
US20060258688A1 (en) 2006-11-16
EP1666041A2 (de) 2006-06-07
EP1666041A3 (de) 2008-04-02
DE69834500T2 (de) 2007-05-03
EP1016407A1 (de) 2000-07-05

Similar Documents

Publication Publication Date Title
ATE325610T1 (de) Xanthinderivative zur behandlung von hirnischämie
NO950297D0 (no) Prolinamidderivater
DE69736441D1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
DK0495982T3 (da) Bicyklisk pyrimidinderivat, fremgangsmåde til fremstilling deraf og farmaceutisk præparat omfattende dette som en aktiv bestanddel
UA27911C2 (uk) Засіб для лікування або запобігання фізіологічних розладів, які викликані надлишком тахікініну
EP0444196A4 (en) Agent for treatment and prophylaxis of ischemic disease of heart or brain
DE60312736D1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
MX9802817A (es) Un agente para curar padecimientos oftalmologicos.
MD1560F2 (en) Cyclic compounds, pharmaceutical compositions on base thereof and methods of treatment of infections or diseases provoked by retroviruses.
DE69029693D1 (de) Hydantoin- oder Imidazolidintrionderivate zur Vorbeugung oder Behandlung von Niereninsuffizienz
DE69500673D1 (de) Arzneimittel zur therapeutischen und prophylaktischen Behandlung von Krankheiten, die durch Hyperplasie der glatten Muskelzellen bedingt sind
SE0002729D0 (sv) Novel compound form
ATE284684T1 (de) Amidderivate zur behandlung neurodegenerativer erkrankungen der netzhaut
KR950032171A (ko) 옥소피리디닐퀴녹살린 유도체
MXPA05014143A (es) Derivados de cumarina para el tratamiento de trastornos oftalmicos.
DE69822937D1 (de) Indolmorphinan-derivate und medikamente zur behandlung/mittel zur vorbeugung von cerebralen störungen
CY1108259T1 (el) Ανταγωνιστες υποδοχεα διεγερτικου αμινοξεος
MXPA03007309A (es) Derivados de amina sustituidos por tiofeno como inhibidores glyt-1.
DE69827706D1 (de) 5-(Heteroaryl)alkyl)-3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid (PBI) Derivate zur Behandlung von Störungen des zentralen Nervensystems
NO993911D0 (no) Remedier/Forebygningsmidler for åndedrettssykdommer
DE69327077D1 (de) Carbamoylpyrrolidon-Derivate zur Behandlung von Depressionen und cerebrovasculären Störungen
SI1553938T1 (sl) Uporaba epotilonskih derivatov za zdravljenje hiperparatiroidizma
AU7962000A (en) Us0027324for eating disorders
ATE103490T1 (de) Derivate der p-guanidinobenzoesaeure zur behandlung der zerebrovaskulaeren kontraktion.
EP1210948B8 (de) Peptid zur behandlung von nervenerkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1016407

Country of ref document: EP

REN Ceased due to non-payment of the annual fee